In addition, STING expression is important for the effect of PARP inhibitors, which have shown efficacy in clinical studies and are used in clinical practice in patients with BRCA germline mutations, mostly in ovarian, prostate, pancreatic, and breast cancer [27,36,37]. This evidence concerns the gene STING1 and breast cancer.